trenbolone acetate
Topkey Pharmaceutical Chemical Manufacturers - TopkeyChem
Email:info@topkeychem.com

Tel: 86-136-888-53671
Fax: 86-136-888-53671
E-mail: info@topkeychem.com
Feedback
Catalogue of Amino Acid
Catalogue of Steroids
2014 China API Fair

Products

Buy nandrolone decanoate Online

nandrolone decanoate
Product Name:
nandrolone decanoate
CAS No. :
360-70-3
:
:

nandrolone decanoate

name   nandrolone decanoate
synonyms   deca-durabolin; 19-nortestoterone decanoate
 
molecular structure   cas # 360-70-3, nandrolone decanoate, deca-durabolin, 19-nortestoterone decanoate
 
molecular formula   c28h44o3
molecular weight   428.65
cas registry number   360-70-3
einecs   206-639-3

The decanoate salt form of nandrolone, an anabolic steroid analog of testosterone with androgenic, anabolic, and erythropoietin stimulating effects. Nandrolone enters the cell and binds to and activates specific nuclear androgen receptors in responsive tissue, including the prostate, seminal vesicles, scrotum, penis, larynx, hair follicles, muscle, and bone. The resulting activated hormone receptor complex translocates into the nucleus and binds to androgen response elements (ARE) in the promoter region of targeted genes, where the complex promotes gene expression necessary for maintaining male sex characteristics. Mimicking the negative feedback mechanism of testosterone, nandrolone decanoate also suppresses the secretion of luteinizing hormone (LH). Furthermore, this agent also stimulates erythropoietin production by enhancing the production of erythropoietic stimulating factors. 

A sterile oleaginous solution containing per mL: Nandrolone Decanoate 200 mg with Benzyl Alcohol 5% as solubilizer/preservative, in Sesame Oil q.s. Nandrolone decanoate (C28H44O3) occurs as a fine, white to creamy white, crystalline powder. It is odorless, or may have a slight odor. Nandrolone decanoate is soluble in chloroform, in alcohol, in acetone, and in vegetable oils. It is practically insoluble in water. 

Nandrolone decanoate is indicated for the management of the anemia of renal insufficiency and has been shown to increase hemoglobin and red cell mass. Surgically induced anephric patients have been reported to be less responsive. 

Nandrolone decanoate has not been tested in laboratory animals for carcinogenic or mutagenic effects. Liver cell tumors have been reported in patients receiving androgenic anabolic steroid therapy (see WARNINGS section). Geriatric patients treated with anabolics may be at an increased risk for prostatic hypertrophy and prostatic carcinoma. 

The safety and efficacy of Nandrolone decanoate in children with metastatic breast cancer (rarely found) has not been established. Anabolic agents may accelerate epiphyseal maturation more rapidly than linear growth in children, and the effect may continue for six months after the drug has been stopped. Therefore, therapy should be monitored by X-ray studies at six month intervals in order to avoid the risk of compromising the adult height. 

Nandrolone decanoate injection is classified as a Schedule III controlled substance under the Anabolic Steroids Control Act of 1990. Nandrolone decanoate injection is intended for deep intramuscular injection only, into the gluteal muscle preferably. Dosage should be based on therapeutic response and consideration of the benefit to risk ratio. Duration of therapy will depend on the response of the condition and the appearance of adverse reactions. If possible, therapy should be intermittent. Nandrolone decanoate should be regarded as adjunctive therapy and adequate quantities of nutrients should be consumed in order to obtain maximal therapeutic effects. For example, when it is used in the treatment of refractory anemia, adequate iron intake is required for a maximal response. 

Nandrolone Decanoate Injection USP, 200 mg per mL is available in vials of 1 mL, in cartons of 20. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

Patients who are on hemodialysis commonly experience muscle wasting and weakness, which have a negative effect on physical functioning and quality of life. The objective of this study was to determine whether anabolic steroid administration and resistance exercise training induce anabolic effects among patients who receive maintenance hemodialysis. A randomized 2 × 2 factorial trial of anabolic steroid administration and resistance exercise training was conducted in 79 patients who were receiving maintenance hemodialysis at University of California, San Francisco–affiliated dialysis units. Interventions included double-blinded weekly nandrolone decanoate (100 mg for women; 200 mg for men) or placebo injections and lower extremity resistance exercise training for 12 wk during hemodialysis sessions three times per week using ankle weights. Primary outcomes included change in lean body mass (LBM) measured by dual-energy x-ray absorptiometry, quadriceps muscle cross-sectional area measured by magnetic resonance imaging, and knee extensor muscle strength. Secondary outcomes included changes in physical performance, self-reported physical functioning, and physical activity. Sixty-eight patients completed the study. Patients who received nandrolone decanoate increased their LBM by 3.1 ± 2.2 kg (P < 0.0001). Exercise did not result in a significant increase in LBM. Quadriceps muscle cross-sectional area increased in patients who were assigned to exercise (P = 0.01) and to nandrolone (P < 0.0001) in an additive manner. Patients who exercised increased their strength in a training-specific fashion, and exercise was associated with an improvement in self-reported physical functioning (P = 0.04 compared with nonexercising groups). Nandrolone Decanoate and resistance exercise produced anabolic effects among patients who were on hemodialysis. Further studies are needed to determine whether these interventions improve survival.

Muscle wasting and weakness are particularly attractive targets for intervention because they are related to loss of function and can be measured and targeted objectively for improvement. Small studies support the possible benefits of two strategies to increase muscle size and strength among patients who are on dialysis. Anabolic steroids, which frequently were used to ameliorate the anemia associated with ESRD before the introduction of recombinant erythropoietin, were noted to cause an increase in serum creatinine along with increases in hemoglobin and hematocrit (14). Although some agents were associated with significant adverse effects, nandrolone decanoate had few adverse effects as a result of its intramuscular route of administration and favorable erythropoietic to androgenic ratio (15). More recently, nandrolone decanoate has been shown to increase lean body mass (LBM) and improve physical performance (16), and resistance exercise training has been shown to increase strength and improve physical performance (17). Neither of these preliminary results has been confirmed, and the relative benefits of these strategies or their potential additive or synergistic effects have not been examined. Therefore, we designed a study to compare changes in LBM, muscle size and strength, physical performance, and self-reported functioning during a 12-wk period among hemodialysis patients who were randomly assigned to one of four groups: (1) Nandrolone decanoate, a synthetic testosterone derivative, by weekly intramuscular injection (ND); (2) weekly placebo injections (PL); (3) lower extremity resistance exercise training during dialysis sessions three times per week plus weekly placebo injections (EX); and (4) resistance exercise plus nandrolone injections weekly (EX+ND).

Nandrolone Decanoate and a placebo that was identical in appearance to the active drug were prepared and supplied to the research pharmacy by Organon, Inc. (Roseland, NJ). Participants were randomly assigned to treatment groups in a 1:1:1:1 manner by the research pharmacist using variable block sizes, which were not known to investigators until the completion of the study. Investigators received a package with 12 vials of study drug or placebo and a card with exercise group assignment from the pharmacy after each participant was assigned.

Nandrolone decanoate or placebo was administered weekly by intramuscular injection by dialysis unit nursing staff, who were blinded to treatment assignment. Men received 1 ml of study drug (200 mg of nandrolone decanoate or placebo), and women received 0.5 ml (100 mg of nandrolone or placebo).

Ninety-one percent of patients who were assigned to receive nandrolone decanoate received 100% of assigned injections; two patients missed one injection each, and one patient discontinued injections after receiving five doses. Patients who were assigned to resistance exercise training completed 89 ± 8% of scheduled sessions (range 69 to 100%). Exercise progressed from an average starting weight of 9.2 ± 4.2 lb for knee extension to 13.9 ± 5.1 lb at the end of the training period. Patients started at 5.6 ± 3.0 lb for hip abduction and progressed to 9.6 ± 4.0 lb; for hip flexion, patients started at 5.3 ± 3.2 lb and increased to 9.5 ± 4.3 lb by the end of the study (P < 0.0001 for all changes from week 1 to week 12).

Changes in body composition are shown in Figure 2 and Table 2. There were significant changes in body weight over time (F = 20.64, P < 0.0001), with patients who received Nandrolone Decanoate gaining weight (P = 0.04), whereas there was no significant weight gain as a result of exercise (P = 0.51). Nandrolone was associated with more remarkable differences in body composition than in weight, with an average increase of 3.1 ± 2.2 kg of LBM (P < 0.001) and decrease of 0.6 ± 1.5 kg of fat mass (P < 0.001). Exercise did not result in a significant increase in LBM but was associated with a significant increase in body fat mass (2.2 ± 2.9 kg for the exercise-only group; P = 0.05). Exclusion of the three patients whose DEXA scans did not occur immediately after dialysis did not alter the results.

Neither exercise nor nandrolone was associated with improvement in gait speed, stair climbing, or rising from a chair (Table 3). Similarly, there were no significant changes in physical activity level as measured by accelerometry or as reported on the HAP. However, exercise was associated with an improvement in self-reported physical functioning on the PF scale of the SF-36 (P = 0.03). In addition, there was a trend toward a reduction in fatigue in the groups that were assigned to exercise (P = 0.06). Finally, there was an increase in anger in the group that received nandrolone decanoate alone but not in the group that received nandrolone and performed resistance exercise training (P = 0.003 for the interaction between nandrolone and exercise).

This study is the largest randomized, controlled trial of exercise or anabolic steroid interventions conducted among dialysis patients. In it, we have shown that weekly nandrolone decanoate treatment and lower extremity resistance exercise training during dialysis for 12 wk were safe and well tolerated. Our results show that both nandrolone decanoate injections and resistance exercise training during hemodialysis have anabolic effects. Not surprisingly, the anabolic effects of exercise training were limited to the muscle groups that were trained, whereas nandrolone had a systemic effect, as evidenced by an increase in LBM and serum creatinine concentration. However, resistance exercise training resulted in increased lower extremity strength and some improvement in quality of life, whereas no such improvement was evident as a result of nandrolone treatment.

We previously reported that 6 mo of treatment with Nandrolone Decanoate increased LBM and improved walking and stair climbing (16). Whereas the body composition changes in this study were similar to those of the earlier study, patients in the nandrolone decanoate arms of our study did not demonstrate the same improvements in physical performance. One possible reason for this discrepancy is the shorter duration of this study. This study was designed to administer the same cumulative dose of nandrolone during a shorter study period. However, it is possible that time is an important factor as well as cumulative androgen dose. Indeed, in the previous study, significant improvements in physical performance were not observed after 3 mo, and there was continued improvement in physical performance between 3 and 6 mo of nandrolone administration. Similarly, the lack of improvement in physical performance in the resistance exercise training groups conflicts with the results of Headley et al. (17), who reported an increase in maximal walking speed and a reduction in the time to perform 10 repetitions of the sit-to-stand test after 12 wk of resistance exercise training. It is possible that the training protocol that we used was less intense than that of Headley et al. Although they did not report the weights lifted, the training took place in a fitness center 2 d/wk using machine weights. It also is possible that Headley’s nonrandomized study included patients who were more motivated or more likely to improve functioning with training. Other potential reasons for the lack of observed effects on physical performance include a true lack of effect as well as a high degree of variability of these tests such that changes as a result of intercurrent illness or other changes in status outweigh any benefit of short-term resistance exercise training or nandrolone decanoate administration.

Nandrolone Decanoate and resistance exercise training seem to be safe options for treatment of the muscle wasting and weakness that commonly are seen among hemodialysis patients. Both of these interventions increased muscle size. Nandrolone had a systemic effect of increasing LBM, whereas resistance exercise training resulted in a training-specific increase in muscle strength as well as an improvement in self-reported physical functioning. Further studies are needed to determine whether these interventions improve survival.

News:

Nandrolone Decaonate for Pharmaceutical and Chemical Processing


 


Related Products :
Getropin HGH
Getropin HGH
Riptropin HGH
Riptropin HGH
LGD-3303 / LGD3303
LGD-3303 / LGD3303
Sidenafil citrate
Sidenafil citrate

Online Support

Skype